Positions Statements & Guidelines
Browse official position statements and clinical practice guidelines developed by ANZCHOG’s multidisciplinary expert groups to support high-quality care and informed clinical practice in paediatric haematology and oncology.
Use of blinatumomab in infants, children and adolescents with B-cell acute lymphoblastic leukaemia
Position Statement | Updated 4 September 2024
To ensure consistency of therapy for infants, children and adolescents being treated for B-ALL across Australia and New Zealand and to enable equity of access, the ANZCHOG Leukaemia & Lymphoma group has published a position statement on the use of blinatumomab in infants, children and adolescents with B-cell acute lymphoblastic leukaemia.
Results from two pivotal paediatric frontline studies have now shown significant improvement in survival outcomes with the addition of blinatumomab to chemotherapy for both infants and children.
To read the full position statement, click here.
Serum asparaginase activity monitoring in children and adolescents
Guidelines | August 2024
Asparaginase is a critical component of modern multi-agent chemotherapy regimens for leukaemia/lymphoma and has been shown to significantly improve outcomes.
To read the full guideline, click here.
Management of children with DIPG
Position Statement | 13 May 2024
The ANZCHOG Central Nervous System (CNS) Tumour Group has recently published a position statement for the management of children with Diffuse Intrinsic Pontine Glioma (DIPG) in Australia and New Zealand.
DIPG is a high-grade glioma and is one of the most aggressive childhood cancers, remaining essentially incurable. Around 20–30 children in Australia and New Zealand are diagnosed with the disease each year.
To read the full, open-access article click here.